DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Carmeliet P, Pallaud C, Deurloo RJ et al.
Plasma (p) VEGF-A and VEGFR-2 biomarker (BM) results from the BEATRICE phase III
trial of bevacizumab (BEV) in triple negative early breast cancer (BC).
Cancer Res 2012;
72 (Suppl. 24) 321s
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.